NCT01584323

Brief Summary

In this study the investigators sought to determine the effects of Pomegranate (Natural pomegranate polyphenol (P. granatum L) extract) :

  1. 1.On the maternal and fetal oxidative stress and inflammation associated with PPROM.
  2. 2.On the time interval from PPROM to delivery and on fetal Ph and apger score.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2012

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2012

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

April 16, 2012

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 24, 2012

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2015

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2015

Completed
Last Updated

April 24, 2012

Status Verified

April 1, 2012

Enrollment Period

3 years

First QC Date

April 16, 2012

Last Update Submit

April 22, 2012

Conditions

Keywords

Preterm premature rupture of membranespomgranateoxidative stresspregnant women with Preterm premature rupture of membranes

Outcome Measures

Primary Outcomes (1)

  • Oxidative Stress

    Serum lipid peroxidation 1. Serum lipids peroxidation 2. Lipid peroxide formation 3. Paraoxonase activity measurements

    Measurments will be first taken at the day of admission (for the mother) and will be assessed immediatly after delivery (mother and newborn)

Secondary Outcomes (1)

  • Obstetrical outcomes

    Measurments will be first taken at the day of admission (for the mother) and will be assessed immediatly after delivery (mother and newborn)

Study Arms (2)

Pomegranate pills

ACTIVE COMPARATOR

treatment with pomgranate pills to women suffering preterm premature rupture of membranes

Dietary Supplement: Pomgranate pills

placebo pills

PLACEBO COMPARATOR

treatment with placebo to women with preterm premature rupture of membranes

Dietary Supplement: Placebo pills

Interventions

Pomgranate pillsDIETARY_SUPPLEMENT

Treatment arm will receive The POMx pomegranate 1,000 mg capsule a day for maximum of two weeks or until they deliver if occurs before The POMx pomegranate 1,000 mg capsule contains at least 800 mg natural polyphenol using a pomegranate polyphenol standard and is comparable to mg/8 oz juice.(attached is confirmation Similarity of Pomegranate Juice and POMx Polyphenols)

Pomegranate pills
Placebo pillsDIETARY_SUPPLEMENT

The placebo group will receive placebo pills , for maximum of two weeks or until they deliver if occurs before The palecbo capsule contains gelatin and lactose. The capsuls are manufactured by the hospital pharmacy.All the components are medically approved fot use during pregnancy

placebo pills

Eligibility Criteria

Age17 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • pregnancy
  • singleton pregnancy
  • preterm premature rupture of membranes
  • gestational age \> 24Wks

You may not qualify if:

  • gestational age \> 24wks
  • fetal anomalies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rambam Health Care Campus

Haifa, Israel

RECRUITING

MeSH Terms

Conditions

Preterm Premature Rupture of the Membranes

Study Officials

  • Ido Solt, M.D

    Rambam Health Care Campus

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
M.D

Study Record Dates

First Submitted

April 16, 2012

First Posted

April 24, 2012

Study Start

April 1, 2012

Primary Completion

April 1, 2015

Study Completion

May 1, 2015

Last Updated

April 24, 2012

Record last verified: 2012-04

Locations